ROCKWELL MEDICAL, INC. (RMTI) research
ROCKWELL MEDICAL, INC.- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $8.65
- As of
ROCKWELL MEDICAL, INC. (RMTI): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-13.
As of . Source: SEC EDGAR filings for RMTI. Method and limitations.
Share the RMTI intelligence card
See the full RMTI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RMTI on one page. Preview it with sample data, then open it live with a free account.
Preview the RMTI dossierActive signals for RMTI
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 41.8%, EPS $-0.34 vs $-0.2397 estimate
- highCONSENSUS_BUY
3 tracked funds increased RMTI this 2026Q1 - institutional consensus
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 149.0% - EPS $-0.1 vs $0.204 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 56.9% - EPS $-0.4 vs $-0.255 estimate
- lowEARNINGS_MISS
Q3-2025: EPS $-0.05 vs $-0.0459 estimate, in line on a near-zero consensus
FREE, NO ACCOUNT
Every signal on RMTI, as it fires
You are seeing 5 of 7 signals recorded on RMTI since 2026-05-17.
The five above landed across 4 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RMTI (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 774374300 · 2026Q2 | $198K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RMTI
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RMTI against its peers
RMTI's operating margin of -6.8% ranks in the 83rd percentile of 14 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | RMTI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 69.3M USD | 33.7M USD | 76 | 18 |
| Gross margin | 16.9% | 41.7% | 11 | 13 |
| Operating margin | -6.8% | -24.5% | 83 | 14 |
| Net margin | -7.7% | -26.6% | 85 | 16 |
| Return on equity | -14.4% | -26.3% | 63 | 14 |
Peers (19): CXXIF, CPHI, IXHL, MRMD, INIS, RAPH, PLNH, ETST, ITHUF, SCYX, TXMD, UPC, AYTU, LEEEF, ZYBT, TLPH, BFRI, HYEX, CWBHF. Left out: GSTK (no annual filing), HSTI (period gap), OPTH (no annual filing), CPIVF (no annual filing), ROMJF (no annual filing), MCUJF (period gap). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (RMTI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more RMTI signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to RMTIand get the insider, 13F, options, and confluence read in one view.